Optimized solution for cancer research
Sensitive detection of low-frequency mutant alleles has extensive implications for cancer research. The accumulation of mutations in oncogenes or tumor suppressor genes is an important aspect of tumorigenesis. The TaqMan Digital PCR Liquid Biopsy assays, combined with the Oncomine cfDNA solutions, offer a comprehensive set of tools for liquid biopsy applications, and in the future may enable noninvasive techniques towards personalized medicine.
The TaqMan dPCR Liquid Biopsy Assays have been wet-lab tested and guaranteed to perform on the Applied Biosystems QuantStudio 3D and Bio-Rad QX-100 and QX-200 systems. Download the quick reference guides for QuantStudio 3D or Bio-Rad QX-100 and QX-200 systems today.
Since these mutations are usually present only in a very small number of cells, they require an assay that delivers high signal-to-noise ratios and low false-positive rates.
By combining TaqMan fluorogenic 5’ nuclease chemistry with digital PCR methodology, researchers are now able to detect low-frequency mutations. Applied Biosystems TaqMan dPCR Liquid Biopsy assays for research have been optimized to work with digital PCR and droplet digital PCR systems to achieve the high performance required to detect and quantify mutations present at very low frequencies.
Our sensitive mutation detection solution includes a set of wet lab-verified TaqMan dPCR Liquid Biopsy assays for research to detect and quantify the most common cancer-related mutations (e.g., EGFR, BRAF, KRAS, PIK3CA, JAK2, and others). These assays, designed using the full bioinformatics power of the TaqMan Assay design pipeline, allow researchers to quantify rare mutants at a prevalence of ≤0.1% (Figure 1).